Key result
High platelet NLRP3 expression linked to more adverse cardiovascular events after PCI.
Why the study?
Little is known about the relationship between platelet NLRP3 levels and ACS severity, or its prognostic value for PCI.
Does high platelet NLRP3 expression predict adverse cardiovascular events in patients with acute coronary syndrome undergoing PCI?
Observational (n=152)
Does high platelet NLRP3 expression predict adverse cardiovascular events in patients with acute coronary syndrome undergoing PCI?
p-value: p=0.004
Platelet NLRP3 expression is elevated in acute coronary syndrome and serves as an independent prognostic biomarker for adverse cardiovascular events following PCI.
Purpose: Little is known about the relationship between the level of platelet NOD-like receptor protein 3 (NLRP3) and the severity of acute coronary syndrome (ACS) or the prognostic value of platelet NLRP3 for percutaneous coronary intervention (PCI). Methods: Platelets collected from 25 healthy subjects, 23 patients with stable angina pectoris (SAP), and 72 patients with ACS were analyzed by Western blotting and real-time fluorescence quantitative PCR (qPCR). A total of 152 patients with ACS who had undergone PCI were included in this study to evaluate the prognostic value of platelet NLRP3 . Results: The levels of platelet NLRP3 in both the healthy and SAP groups were clearly lower than in the ACS group ( P < 0.001). According to the Pearson correlation analysis, the expression of platelet NLRP3 was closely related to the mean platelet volume (MPV), left ventricular ejection fraction (LVEF), the Gensini score, and the Global Registry of Acute Coronary Events (GRACE) score (all P < 0.001). Multivariate logistic regression analysis identified NLRP3 as an independent risk factor for adverse cardiovascular events (ACEs) after PCI ( P =0.004). The proportion of patients with high NLPR3 expression (the NLRP3 -high group) remaining free of adverse events for 3 years was remarkably lower than that in patients with low NLPR3 expression (the NLRP3 -low group; P =0.024). The NLRP3 -high group had a significantly higher proportion of patients with interleukin-1β–expressing (20.4%± 6.1%) platelets than the NLRP3 -low group (10.7%± 3.5%, P < 0.001). Moreover, the NLRP3 -high group exhibited higher platelet activity, as indicated by increased PAC-1 binding and CD62P expression, compared with the NLRP3 -low group ( P < 0.001). Conclusion: These results indicated that platelet NLRP3 was a novel potential prognostic factor for patients with ACS that underwent PCI.
No takes yet. Share an insight, caveat, or question.
Peng et al. (2020) conducted an observational in Acute Coronary Syndrome (n=152). High platelet NLRP3 expression vs. Low platelet NLRP3 expression was evaluated on Adverse cardiovascular events (ACEs) after PCI (p=0.004). High platelet NLRP3 expression was an independent risk factor for adverse cardiovascular events after PCI (P=0.004) and was associated with lower 3-year event-free survival (P=0.024).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: